01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
20:18 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

Ionis begins Phase I/IIa trial of AD candidate IONIS-MAPTRx

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) began a Phase I/IIa trial of IONIS-MAPTRx to treat mild Alzheimer’s disease. The double-blind, international trial will evaluate 4 dose levels of once-monthly intrathecal injections of IONIS-MAPTRx (BIIB080) in about 44...
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Company News

Isis Pharmaceuticals Inc, Biogen Idec deal

Isis received a $10 million milestone payment from Biogen under a 2013 deal under which the companies are using Isis’ antisense technology to identify and validate targets. The milestone was triggered by IND-enabling studies for...